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The socio-economic impact of FMD 
 
Theo Knight-Jones  
 
FMD in endemic countries causes a global economic impact, due to production losses 
and vaccination costs, of around US$6.5 to 21 billion per year [1]. This does not include 
the impact of loss of trade or restricted development of the livestock sector, which are 
potentially enormous. Much of this burden falls on Asia, with China and India the worst 
affected. Estimated production losses for affected cattle range between US$100 to 
US$370 per case [2-6]. In addition, losses from FMD outbreaks in free countries average 
at >US$1.5 billion per year, one of the most notorious being the UK 2001 outbreak with 
estimated losses of >US$9 billion [7]. 
 
Recent studies of FMD incidence in East Africa found that 70–90% of herds experienced 
clinical FMD each year [8, 9]. This is in line with sero-prevalence studies, which find 
that in many areas of Africa and Asia about a third of young cattle are infected with FMD 
each year.  
FMD incidence is highest in regions where smallholder farming is commonplace. One study in South-East Asia estimated that 
outbreaks resulted in a reduction in household income of 4-12% [4], in parts of Laos they may account for 60% of annual household 
income [10]. The impact of FMD on food security is exacerbated by a reliance on livestock as a means of traction by many 
smallholders in Asia and Africa [11, 12]. Studies in Laos and Cambodia estimated that affected cattle lose a quarter to three-quarters 
of their original value [13, 14]. As cattle play an important role as assets that are cashed in at times of need, this has a severe impact 
on livelihoods. 
 
This high incidence in endemic countries translates to a high risk of virus incursion in free  countries. Countries that have eradicated 
FMD face ongoing costs from periodic outbreaks and the costs of maintaining preparedness. Many countries reduce the impact of 
the disease with extensive ongoing vaccination programmes. The global scale and costs associated with these programmes are vast 
with billions of doses administered annuallyThe rewards of successful FMD control are such that some nations vaccinate all cattle 
as much as five times a year, monopolising the resources of the veterinary services. The costs associated with mass vaccination 
discourage some countries from attempting to control FMD. Successful FMD control takes many years or even decades, and 
programmes that are not fully committed are unlikely to reduce disease impact. 
 
FMD losses in India, due to deaths, milk loss, draught losses and treatment costs were estimated to be US$2.7–3.6billion [15] and 
control is now a priority. Mass vaccination will require billions of doses and biosecurity measures, if effectively implemented, cause 
additional indirect losses. However, in the long term, such approaches have brought significant returns in South America and 
elsewhere. 
 
The impact of FMD outbreaks in free countries has been studied in detail and the devastation FMD causes is well understood. Yet 
our knowledge of FMD impact in endemic countries has, until recently, largely been based on hearsay. From this absence of 
evidence, FMD control in endemic countries has often been deemed a lesser priority by governments and international funding 
agencies, particularly for countries without the potential to benefit from FMD free export markets. It has been argued that, in 
southern Africa, only wealthy farms benefit from FMD free status [16], whilst the control costs are carried by the tax-paying public 
at large. Others have stated that a significant proportion of the benefits of international export filter down through the supply chain 
to low-income households [17]. 
 
Although mortality from FMD is low, the continued, and widespread, high disease incidence clearly leads to a heavy burden of 
disease at the population level. However, more studies are needed that measure this impact in order to fill the void of evidence. 
Benefit-cost analysis requires estimates of the impact of control. Although FMD control measures have proved to be effective in 
much of the world, efforts to control FMD in developing countries have experienced variable success. Guidance is needed, and 
control programmes in this setting need to be better evaluated and their impact quantified. As for other areas of FMD research, 
despite many decades of progress, there is much that needs to be done. 
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Development of molecular therapeutics to   
control early infection during FMD outbreaks 
 
G R Reddy, H J Dechamma & V Umapathi 
Indian Veterinary Research Institute, Bangalore, India 
 
Current FMD vaccines do not induce a protective response until 7 
days post-vaccination. Due to the short incubation period, signs of 
disease can appear as early as 2 days post-exposure. This situation 
has underlined the importance of developing antiviral strategies 
capable of limiting the multiplication of the infective virus and 
stopping the spread of the disease. To develop therapeutics which 
can stop the multiplication of FMDV at the early stage of infection 
we selected two approaches: i) interferon based, and ii) small 
interfering RNA based.  
 
Interferon based therapeutics 
3’UTR RNA was able to induce interferon(IFN) α production when 
transfected into PK15 cells and inhibited FMDV replication as 
analysed by qRT-PCR.  FMDV 3’ UTR transfected PK15 cells were 
infected with 0.1 pfu/cell FMD type O virus. Viral RNA in the 
infected cells was quantified by qRT-PCR. Inhibition of viral 
replication in the cells pre-transfected with UTR RNA was observed.  
Further, UTR pcDNA plasmid was able to induce IFN α production 
when transfected into PK15 cells and inhibited FMDV replication as 
analyzed by qRT-PCR. 
 
The sequence coding for IFN λ was cloned into pShuttle 2, an 
adenoviral transfer vector, and the presence of the insert was 
confirmed by PCR. The linearised vector along with the linearised 
adenovirus was transfected into HEK 293 cells.  Recombinant 
adenovirus with IFN λ was isolated and confirmed by PCR. The 
recombinant adenovirus expressing IFN λ will be tested for its 
therapeutic potential. 
 
Small interfering RNA based therapeutics 
Small interference RNA (siRNA) is a rapid and effective antiviral 
approach where double-stranded RNA induces the homology-
dependent degradation of cognate mRNA. FMDV 3C protease 
(3Cpro) is the principal enzyme involved in processing the precursor 
to a proteome of virus, thereby making it a very attractive target for 
the design of antivirals. By using bioinformatics computer programs, 
all FMDV genome sequences in public-domain databases were 
analysed. Based on the results of homology analysis, four specific 
siRNAs targeting the conserved 3C region of FMDV were prepared 
and four siRNA-pSIREN expression vectors under the control of the 
U6 promoter were constructed. pCDNA3C FMDV and pCDNA 
3CFMDV-GFP marker clones were also produced to evaluate the 
gene silencing efficiency using real-time qRT-PCR, and showed a 4-
fold reduction of 3C transcripts in BHK-21 cells. On further analysis 
of four siRNA’s,  Si1 and Si2 showed a 100-fold decrease in viral 
quantity compared to the virus control after 12 hr infection with 1 
moi FMDV O.  The results demonstrated that transfection of BHK-
21 cells with siRNA-expressing plasmids significantly decreased the 
FMDV O titre. A 3-fold reduction in viral growth was observed 
when BHK-21 cells were transfected with anti-FMDV siRNAs and 
treated with 50% tissue culture infective dose (TCID50) of FMDV O, 
compared to control cells. 
 
3ABC antigen based indirect ELISA and a 
rapid test kit for FMD DIVA 
 
M Hosamani, S H Basagoudanavar, B P Sreenivasa, R P 
Tamilselvan, P Saravanan &  R Venkataramanan 
Indian Veterinary Research Institute, Bangalore, India 
 
FMD is major livestock disease of transboundary importance 
affecting cloven-hoofed animals including cattle, pigs, goats and  
sheep. Tests based on assaying non-structural proteins (NSP) 
antibodies in animals, particularly targeting the 3ABC antigen, have 
been widely used for differentiating infected from vaccinated 
animals. In our laboratory, an in-house, indirect ELISA was 
developed for application in multiple species. This is an 
improvement over the earlier reported ELISA system that was 
species specific. The test uses recombinant 3ABC protein expressed 
in insect cells using a baculovirus system. The assay has been 
validated by testing serum samples representing an endemic 
situation. Its performance was compared with a similar commercial 
kit.  
 
Though highly sensitive, use of ELISAs requires trained personnel 
to perform and interpret the test results. Tests that don’t need 
sophisticated instruments and trained manpower are a valuable 
addition to the available tools for diagnosis of FMD infected animals 
under field conditions. Keeping this in mind, the institute, in 
collaboration with M/s ubio Biotechnology, India, developed a rapid 
test for detection of NSP antibodies. The lateral flow device (LFD) 
test has the advantage that it does not require cold chain for transport 
or storage, and results can be read with the naked eye without the 
need for instruments and trained personnel.  This pen-side diagnostic 
can be performed in 10–15 minutes by veterinarians or farmers.  
  
Rapid LFD Test performance 
The LFD assay was compared with an indirect ELISA using a panel 
of known positive and known negative sera available in the lab. 
Diagnostic sensitivity and specificity were found to be 87.4 and 
97.4, respectively, in comparison to the ELISA.  
 
Sera collected from multiple vaccinated animals that received double 
the recommended dose of vaccine were also tested to verify the NSP 
content in the vaccine used. Bull calves received three doses of 
vaccine within a 2 month period and sera were collected 28 d after 
the last booster. About 60% of these animals showed reactivity in 
ELISA while the LFD test showed positivity in 27% animals. The 
vaccine used here was not certified to be free from NSP 
contaminants. 
 
The assay has been optimised to screen different FMD target species 
of animals including sheep, goat, cattle and buffalo, to validate the 
assay compatibility using either blood or serum (Figure 1). Both the 
diagnostics have been transferred to M/s ubio Biotechnology, 
Kochin for commercial scale up. The kit is marketed at a price of 
less than 1 USD per sample in India by M/s Ubio Biotechnology.   
Figure 1: The test is useful to detect NSP antibodies from either 
serum, plasma or blood. Blood samples collected from 
experimentally infected bull calves can be directly applied in the 
LFD assay. Whole blood collected with anticoagulant in a tube or 
fresh blood collected from ear puncture (using a lancet) can be 
collected in a dropper and applied after dilution in the diluent tube 
provided.  
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Accurate, timely diagnosis is essential for control, monitoring and 
eradication of FMD. Currently, samples are tested at reference 
laboratories: a lengthy process which delays critical decision 
making. Reverse transcriptase loop-mediated isothermal 
amplification (RT-LAMP) and mobile rRT-PCR provide a realistic 
option for rapid, sensitive, in situ detection. Having adapted [1] and 
validated a lyophilised RT-LAMP (visualisation by fluorescence or 
molecular LFD) and lyophilised rRT-PCR [2] in the laboratory, we 
travelled to Nakuru, Kenya (as part of the EuFMD Commission ‘real 
time’ FMDV training course) in November 2013 and Morogoro, 
Tanzania in June 2014 for the start of field trials. 
 
During the trip to Nakuru, a concordance study was performed in 
situ between the lyophilised mobile rRT-PCR assay (using the 
Enigma® FL) and antigen LFDs (Ag-LFD). Six cattle, at different 
stages of clinical FMDV infection, were sampled for epithelium, 
serum and vesicular fluid. Epithelial samples were processed using 
antigen extraction kits (Svanova, Sweden) before adding to the 
mobile rRT-PCR assay; serum and vesicular fluid were added neat. 
The rRT-PCR correctly detected FMDV in the clinical samples and 
showed increased analytical sensitivity comparatively to Ag-LFDs. 
It was of priority throughout the trip to ensure that the Nakuru team 
were engaged with our activities and were provided with 
opportunities to partake in the work (Figure 1). 
 
Figure 1: a) FMDV infected cattle in Nakuru, b) the mobile         
laboratory, c) Eunice Chepkwony setting up the Enigma® FL  
The beginning of the trip to 
Tanzania (June 2014) was 
spent  in  engagement 
activities with members of 
Sokoine University staff, 
particularly focusing on 
technology transfer of 
mo lecu la r  f ie ld -b ased 
equipment (Enigma® FL for 
rRT-PCR and Genie® II for 
RT-LAMP). Training was 
p r o v i d e d  i n  s a mp l e 
p r e p a r a t i o n ,  F M D V 
detection platforms and result analysis (Figure 2). During this time 
we tested the Genie® II, molecular LFDs, Enigma® FL and Ag-LFDs 
on thirteen archived epithelial suspensions, which had been 
previously characterised as positive or negative for FMDV by rRT-
PCR (Tanzania Veterinary Laboratory Agency). Epithelial 
suspensions were processed by dilution in nuclease free water before 
adding to RT-LAMP; suspensions were run neat on the Enigma® FL. 
High concordance was seen between RT-LAMP, molecular LFDs 
(RT-LAMP-LFD’s) and rRT-PCR. Ag-LFDs consistently displayed 
lower analytical sensitivity compared to RT-LAMP-LFD and rRT-
PCR. No amplification was detected in any of the known negative 
samples. 
 
We then began field trials at two Maasai farms (Morogoro, 
Tanzania). No acute FMD infection was encountered, therefore eight 
Ankole crossbred cattle, known to have been infected with FMD one 
month previously, were selected and sampled for oesophageal-
pharyngeal (OP) fluid and serum. Samples were diluted in nuclease 
free water before adding to RT-LAMP/RT-LAMP-LFD and run neat 
on rRT-PCR (Figure 3). Good concordance was shown between the 
Genie® II, molecular LFD, Ag LFD and the Enigma® FL, with 
FMDV detected in the OP fluid of two cattle. For RT-LAMP/RT-
LAMP-LFD, results were obtained in less than 30 minutes from OP 
collection to result calling; melt curve analysis confirmed LAMP 
amplicons to be FMDV specific. No FMDV was detected in serum 
samples.  
Figure 3: a) OP fluid sample preparation with the Maasai, b) 
Setting up the Genie® II, c) Setting up the Enigma® FL 
Realising the potential of simple molecular tools for field diagnosis of foot-and-mouth 
disease: A report from the field 
Figure 2 :Training the Sokoine staff how 
to interpret molecular LFDs and Ag-LFDs  
A 
B 
C 
A 
B C 
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Indian Veterinary Research Institute, Bangalore, India 
 
Liquid-phase blocking enzyme-linked immunosorbent assays (LPB-
E) are accepted tests for post-vaccination monitoring.  The current 
method of LPB-E utilises chemically inactivated FMDV as the 
diagnostic antigen. However, this practice is risky due to the need 
for handling live FMDV during antigen preparation. 
 
Empty virus-like particles (VLPs) generated by baculovirus 
expression systems retain the antigenicity of the whole virus antigen. 
Considering the fact that LPB-E is extensively employed for sero-
monitoring in FMD control programmes, the baculovirus expressed 
empty capsid antigens are valuable reagents. The developed 
technology would make consistent antigen availability without batch 
to batch variation.  Further, the non-infectious nature of empty VLPs 
may widen the acceptability of empty capsid reagents for diagnostic 
assays across geographical barriers. We have demonstrated that the 
test performance of VLP based LPB-E was comparable with 
conventional LPB-E, qualitatively as well as quantitatively, thus 
emphasising the diagnostic application of recombinant FMDV 
VLPs. Analysis of the LPB-E results showed that titres obtained 
using empty capsid antigen were significantly similar with those 
obtained by inactivated virus antigen. The recombinant empty capsid 
antigen when evaluated against sera with a broad range of antibody 
titres, from low to high, showed good correlation with inactivated 
virus antigen. 
 
Our last day in Tanzania was spent at the Tanzanian Veterinary Laboratory Agency (TVLA), providing a training session in methods 
including Ag LFDs, rRT-PCR and RT-LAMP/RT-LAMP-LFD (Figure 3). To demonstrate the techniques, four known FMDV positive 
epithelial were assayed using Ag-LFDs, Genie® II and Enigma® FL. High concordance was seen between all platforms. 
 
The ability of RT-LAMP/RT-LAMP-LFD 
and mobile rRT-PCR to utilise simple 
sample preparation, amplification and 
detection methods offers promise for 
rapid in situ FMD diagnosis. Further trials 
are planned for testing RT-LAMP on 
other clinical sample types and acutely 
infected animals in situ in the Serengeti, 
Tanzania in September.                                                                    
 
1.Arch Virol, 2006, 151(6): 1093-106. 
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Figure 4: a) Demonstration of field-based molecular tests, b) Staff from TVLA and The Pirbright Institute 
Type of cattle serum 
Number of 
samples 
Empty capsid antigen LPBE Inactivated virus antigen LPBE 
Titre (Log10) ≤1.5 Titre(Log10)  ≥1.8 Titre (Log10) ≤1.5 Titre(Log10)  ≥1.8 
Unvaccinated 25 25 0 25 0 
Vaccinated 127 8 119 10 117 
Total 152 33 119 35 117 
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Application of baculovirus expressed virus-like particles in liquid-phase blocking ELISA 
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S A Bhat, P Saravanan & S H Basagoudanavar 
 
Indian Veterinary Research Institute, Bangalore, India 
 
Vaccination is a well-accepted strategy for control of FMD in 
endemic countries. Currently, chemically inactivated virus antigens 
are used for preparation of FMD vaccine. To develop a non-
infectious and safe recombinant vaccine, we expressed the structural 
polypeptide of FMDV (O/IND/R2/75) using a baculovirus 
expression system.  
 
We showed that inclusion of mutated viral 3C protease in frame with 
the polypeptide (P1-2A) enhanced the yield of structural proteins. 
The structural proteins retained antigenicity and assembled into 
empty virus-like particles (VLPs). Immunisation of guinea pigs with 
purified fractions of the VLPs resulted in comparable humoral and 
relatively higher cell-mediated immune responses by 4 weeks, when 
compared to conventional vaccine in guinea pigs.  Further, up to 
70% of the VLP immunised guinea pigs were protected against 
challenge with homologous guinea pig-adapted virus. Our results 
highlight the application of recombinant FMDV VLPs in FMD 
vaccination. 
 
Baculovirus-expressed FMDV O VLPs reacted in a sandwich-
ELISA indicating antigenicity which could be exploited further for 
use as an alternative antigen in diagnostic assays. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: Result of sandwich ELISA showing reactivity of purified 
fractions of baculovirus expressed proteins, with homologous anti-
146S sera. 
 
Table: Protection in guinea pigs immunised with either inactivated 
conventional vaccine or capsid antigens derived from recombinant 
baculoviruses, upon challenge with FMDV type O (1000 GPID50) on 
28 dpv. 
Group 
No. of guinea pigs without 
clinical  disease/challenged 
% 
protection 
Control (PBS) 0/10 0 
Conventional vaccine 9/10 90 
O-P1-2A-3CWT 5/8 62 
O-P1-2A-m3CG38S 
F48S 
7/10 70 
Baculovirus expressed VLPs of FMDV Type O as new generation antigen  
B P Sreenivasa1, J K Mohapatra2, S J Pauszek3, M Koster3, M 
Hosamani1, P Saravanan1,  B Pattnaik2, Teresa de los Santos3, 
R Venkataramanan1*, M J Grubman3 & L L Rodriguez3 
 
1
Indian Veterinary Research Institute, Hebbal, Bangalore, India 
2
Project Directorate on Foot and Mouth Disease, Mukteswar 
(Uttarakhand), India 
3
Plum Island Animal Disease Center, North Atlantic Area, 
Agricultural Research Service, US Department of Agriculture, 
Greenport, New York, USA 
 
FMD is considered a major threat to animal health globally. 
Inactivated vaccine is being used worldwide for the control of the 
disease. New vaccine platforms have also been explored in the last 
few years with the human adenovirus 5 vector (Ad5) platform being 
the most successful molecular vaccine to date. One such vaccine 
developed by scientists of USDA has been licensed for manufacture. 
 
In order to test the efficacy of Ad5-FMD vaccines in endemic 
settings like India, a collaborative project was initiated between the 
Indian Veterinary Research Institute Bangalore, Project Directorate 
on FMD, Mukteswar and Plum Island Animal Disease Center, New 
York. Using the adenovirus vector platform developed by USDA, 
recombinant Ad5-FMD constructs expressing capsid proteins of 
Indian FMD vaccine strains (O IND R2/75, A IND 40/2000 and 
Asia 1 IND 63/72) were made. The Western blot experiments 
confirmed that all the recombinants tested were expressing FMDV 
capsid proteins. The recombinant viruses were also tested for FMDV 
type specificity using sandwich ELISA (Fig.1 & 2). 
 
 
Development and evaluation of adenovirus vectored FMD vaccine using Indian vaccine 
strains of FMDV 
Figure 1: Confirmation of FMDV type O and A capsid expression 
by Sandwich-ELISA  
Figure 2: Confirmation of FMDV Asia-1 capsid expression by  
Sandwich-ELISA 
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Vaccination trial in cattle 
 
The proof of concept vaccination trial in Indian cattle was carried out as follows: 
Six months to one year-old indigenous breed male calves purchased from a local animal market were screened for antibodies against three 
serotypes of FMD virus (O, A and Asia1) and hAd5 virus. Animals that tested negative (<0.9 log10) for FMD and hAd5 antibodies were 
used for a vaccination trial in a six animals per group format. The animals were inoculated subcutaneously with Ad5-FMDV monovalent or 
Ad5-FMDV trivalent vaccine in 2 ml phosphate buffered saline (PBS). Ad5-Blue virus was used as a vector control and inactivated oil 
adjuvanted trivalent vaccine obtained from a commercial vaccine manufacturer was used as positive vaccine control (inoculated 
intramuscularly). Monovalent Ad5-FMD vaccine groups were inoculated with 5x109 pfu per animal. Trivalent Ad5-FMD vaccine was 
prepared by mixing 5x109 pfu of each of the monovalent vaccine in a final volume of 2ml per dose. Vaccines were inoculated at two sites 
on either side of the neck. All the animals used in the experiment were co-housed.  
 
To assess the humoral immune response in the vaccinated animals, post-vaccinate sera was collected on days 7, 14, 28 and 63. Serum 
samples were collected on 14 and 28 days after booster vaccination.  Neutralising antibody titres were estimated by virus neutralisation test 
as well as liquid phase blocking ELISA (LPBE). 
 
The results of the cattle immunisation study can be summarised as follows: 
 In the monovalent Ad5-FMD type O group, five of six animals (83%) sero-converted. Out of five responders, peak antibody titres 
(log10SN50) were 2.1 in two animals and in the range of 1.36 to 1.65 in the remaining three animals. Except one animal which 
maintained peak titre of 2.1, antibody titres declined in all the responders and by week 9, titres declined below 1.65 (Fig.3). In LPBE, all 
six animals (100%) showed detectable antibody titres with peaks ranging from 1.65 to 2.56. 
 
 In the monovalent Ad5-FMD type A group, four of six animals (67%) developed a specific antibody response. These four responders 
showed peak antibody titres (log10SN50) of 1.5, 1.65, 1.8 and 2.4. Except one animal which maintained peak titre of 1.95, antibody titres 
declined in all the responders and by week 9, titres declined below 1.65 (Fig.4). In LPBE, three out of six animals (50%) showed 
detectable antibody titres with peak titres ranging from 1.65 to 2.26. 
 In the monovalent Ad5-FMD type Asia-1 group, two of six animals (33%) developed a specific antibody response with a peak antibody 
titre (log10SN50) of 1.36. Except one animal which maintained a peak titre of 1.95, antibody titres declined in all the responders and by 
week 9, titres declined below 1.65 (Fig.5). In LPBE, five of six animals (83%) showed detectable titres with a peak titre ranging from 
1.65 to 1.96. 
 
 In the trivalent Ad5-FMD group, detectable levels of antibodies were found in one of six animals (16%) for type O (Fig.3) and two of six 
animals (33%) for type A (Fig.4). None of the animals responded for type Asia-1 (Fig.5). By LPBE test, a titre of ≥1.65 was detected in 
four of six animals (67%) for type O, two of six animals (33%) for type A and three of six animals (50%) for type Asia-1. 
 
 All animals vaccinated with standard inactivated trivalent vaccine sero-converted against all the three types of FMDV (Fig. 3, 4 & 5). 
 
 Following booster immunisation in monovalent Ad5-FMD groups and inactivated 
vaccine groups, a significant increase in neutralising antibody response was 
observed when sera collected on days 14 and 28 were tested by VNT (Fig.3, 4 & 
5) and LPBE. 
 
From the observations, we can conclude that: 
 The vaccination trial in Indian cattle showed that after primary immunisation, the 
animals responded comparatively better in monovalent Ad5-FMD O & A groups 
than Ad5-FMD Asia-1.  
 Trivalent Ad5-FMD vaccine did not induce significant antibody responses 
compared to monovalent Ad5-FMD vaccines. 
 Neutralising antibody titres increased significantly after booster immunisation. 
 Ad5-FMD vaccinated cattle had lower titres than the animals immunised with 
inactivated oil adjuvanted trivalent FMD vaccine. 
 Neutralising antibodies against Ad5V appear to peak early and decline drastically 
(Fig.6). 
 
Figure 5: Mean neutralising antibody titre 
in Ad5-FMD (type Asia-1) vaccinated cattle 
Figure 4: Mean neutralising antibody titre 
in Ad5-FMD (type A) vaccinated cattle 
Figure 3: Mean neutralising antibody titre 
in Ad5-FMD (type O) vaccinated cattle  
Figure 6: Mean neutralising antibody response 
against Ad5 virus in cattle following vaccination with 
recombinant Ad5-FMD viruses 
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Reinhold Kittelberger1, Charles Nfon2, Richard Clough1, 
Andrew McFadden1, Zhidong Zhang2, Richard Spence1 and 
Soren Alexandersen2 
 
1Investigation and Diagnostic Centre, Ministry for Primary 
Industries, Upper Hutt, New Zealand 
2National Centre for Foreign Animal Disease, Canadian Food 
Inspection Agency, Winnipeg, Canada 
 
Introduction 
 
FMD has never occurred in New Zealand and an incursion would 
have a major economic impact on the country, with agriculture being 
an important contributor to the economy. Whilst most of New 
Zealand’s agriculture involves sheep (30 million) and cattle (10 
million) farming, deer farming is also important. More than 1 
million deer are farmed, predominantly red deer (Cervus elaphus 
elaphus). There is also a substantial feral deer population present. 
Furthermore, deer and other livestock species are often farmed 
alongside each other, which may lead to spread of the virus between 
them. 
 
It has been reported that FMDV infected deer often do not show 
clinical signs1). This means that laboratory testing is required in 
order to identify infected deer during an incursion and the 
subsequent proof-of-freedom phase. A large number of test methods 
for FMD are available2) but their appropriateness for deer is currently 
unknown, as these tests had been developed for other livestock 
species, namely cattle, sheep, goats and pigs. The aim of this project 
was to evaluate a number of FMD test methods for use in red deer. 
 
The FMD in Deer Project is a collaborative project between the 
Animal Health Laboratory (AHL), Ministry for Primary Industries 
(MPI), New Zealand, and the National Centre for Foreign Animal 
Disease (NCFAD), Canadian Food Inspection Agency (CFIA), 
Winnipeg, Canada. The project consists of two components: the 
Winnipeg Component and the New Zealand Component. 
 
Winnipeg Component 
 
The Winnipeg Component was completed in November/December 
2013. Ten red deer were experimentally infected with an O-strain 
FMDV. Samples were regularly collected over a 4 week period: 
nasal swabs, oral swabs, probang samples, whole blood and serum. 
In addition, lesion samples were collected. Samples were tested by 
IRES and 3D real-time RT-PCR, virus isolation, virus neutralisation 
test (VNT), two types of SP O ELISAs, four types of NSP ELISAs 
and an NSP antibody penside test. Some samples were also tested by 
two antigen penside tests and in the O-serotype antigen ELISA. 
Experimental infection was the only way to obtain samples from 
infected red deer, as field samples do not exist worldwide. 
 
New Zealand Component 
 
In the New Zealand Component, which is currently underway at the 
AHL, the diagnostic specificity will be determined for those test 
methods that performed well with experimentally infected animals. 
A total of 1000 serum samples will be tested in SP O- and NSP 
ELISAs and a penside test, and another 200 serum samples with 
matching nasal swabs will be tested in both RT-PCR assays. 
Furthermore, with inactivated serum samples obtained from the 
experimentally infected animals from the NCFAD, another SP O 
ELISA that has recently become available will be evaluated at the 
AHL. In addition, a proportion of the RNA samples from Winnipeg 
will be used for evaluating sensitivity and specificity in AHL’s own 
RT-PCR assays. 
 
Findings and Discussion 
 
Not unexpectedly, one outcome of this project was that deer are 
difficult to infect3,4). Of the 10 experimentally infected red deer, only 
one animal became clinically affected, despite a relatively high viral 
dose used for inoculation. Six more animals developed a humoral 
immune response after re-inoculation. At this stage, it can be said 
that one of the commercial SP O ELISAs and one of the commercial 
NSP ELISAs performed comparably well to the reference methods 
used at the NCFAD, which were virus isolation, VNT,  and the two 
in-house antibody ELISAs, an NSP ELISA and an SP O ELISA. 
Both RT-PCR assays performed well. We would like to emphasise 
that not every commercially available test method worked 
satisfactorily for red deer. 
 
Detailed results of this project will be published in due course in a 
scientific journal. 
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Cellular bases of the development of the anti-FMDV local antibody response in cattle 
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FMD has been consistently considered a major threat on a 
worldwide scale for livestock industries and international trade of 
meat and meat derivatives. Work proposed here is aimed at 
addressing current gaps in basic knowledge related to immunity to 
FMDV in cattle, focusing on the mechanisms underlying the 
induction of memory responses by FMD vaccination upon infection 
via the oronasal route and its impact on the further protection to the 
disease.  
 
Research conducted in collaboration between PIADC and the 
Institute of Virology at INTA, have clearly indicated that primary 
immune reactions after oronasal infection or parenteral vaccination 
generate antibody responses at mucosal and systemic levels (J Virol 
87:2489-2495). Similarly, induction of secondary responses in 
FMDV vaccinated cattle after aerogenous infection is evident at both 
systemic and local levels. However, vaccination/infection-related 
factors (viral antigen persistence, recruiting signals, etc) that trigger 
this FMDV-specific B-cell anamnesis, as well as its origin and time-
course, remain unclear. Whether the vaccine antigen reached the 
local lymph tissues (alone or associated to antigen-presenting cells) 
or if FMDV-specific B-lymphocytes migrated from the vaccination 
site to other lymphoid tissues is also unknown. In the same way, 
contribution to protection of these mucosal FMDV-specific antibody 
responses is yet to be elucidated. We hypothesise that parenteral 
vaccination promotes generation of resident B-cell memory cells in 
mucosal lymph nodes and that the induction of local secondary 
responses at the respiratory tract of vaccinated cattle after oronasal 
infection play a role in preventing the virus to gain access to blood 
stream and generalise the infection to secondary replication sites in 
foot (and other) epithelial tissues. 
Wilna Vosloo, Jacquelyn Horsington, Nagendra Singanallur 
 
Australian Animal Health Laboratory, Geelong, Australia 
 
Australia is in the enviable position that it has not suffered an 
outbreak of FMD since 1872.  This freedom from disease, together 
with the absence of other diseases such as BSE, has provided the 
country with trade advantages worth billions of dollars.  In fact, it is 
estimated that a widespread outbreak of FMD could lead to losses of 
up to 50 billion Australian dollars over a 10 year period, mostly due 
to trade embargoes and market losses.  FMD is therefore a severe 
risk that warrants investment in risk mitigation and research.  
However, despite the presence of a national state-of-the-art high 
containment facility, the risk of working with live FMD virus is 
deemed too high, and any such research has to be done offshore in 
collaboration with partners.  The FMD Risk Management Project, 
started in 2010, is funded by Meat and Livestock Australia and 
Animal Health Australia with support from all major livestock 
industries, and is managed by the CSIRO-Australian Animal Health 
Laboratory (AAHL).  AAHL has relied heavily on the GFRA 
partners to perform a number of vaccine efficacy studies using 
vaccine strains held in the Australian vaccine bank against viruses 
currently circulating in South East Asia, using cattle, sheep and pigs.  
The outputs from this project aims to ensure the Australian livestock 
industries, and the Australian community, will be better prepared to 
minimise the inevitable disruption to trade that would be caused by 
an outbreak of FMD. 
 
Some of the highlights of these collaborations include testing a 
newly developed vaccine developed from the 2010 outbreak virus in 
South Korea in collaboration with Merial and The Pirbright Institute.  
This vaccine was compared with O1 Manisa for efficacy in cattle 
and pigs.  In collaboration with the National Centre for Foreign 
Animal Diseases, Canada, we tested the protective capacity of high 
potency vaccination (>6 PD50) with O1 Manisa 4 days prior to 
challenge with O/SKR/2010 by direct contact with infected sheep.  
A second trial was of similar design but used the A22 Iraq vaccine 
and the A/VIT/15/2012 strain as challenge.  Further studies were 
done in sheep at the Plum Island Animal Diseases Centre, USA 
where different routes of infection (intra-nasopharyngeal instillation, 
aerosol exposure, coronary band inoculation and direct contact) and 
different vaccine doses were tested using the O1 Manisa vaccine and 
challenging with O/SKR/2010.  Although not a GFRA partner, 
collaborative studies were done in Vietnam as part of capacity 
building and also to introduce GFRA activities to the region.  The 
O1 Manisa and A Malaysia 97 vaccines were tested against the type 
O and A viruses, respectively, currently circulating in SEA by 
vaccinating pigs and challenging at early time points post-
vaccination.  In addition, the experiments were designed to 
determine whether vaccination lowers virus excretion thereby 
preventing infection of pigs in close, but not direct contact with 
vaccinated and infected animals.  As part of the vaccine efficacy 
testing in pigs, the use of cotton ropes as a diagnostic tool for FMDV 
in pigs was investigated (Vosloo et al. Transbound Emerg Dis. 2013 
Dec 11. doi: 10.1111/tbed.12196.).  The ease in which oral fluid 
samples from ropes were collected and extracted makes rope 
sampling an extremely useful, non-invasive method of sample 
collection that may complement FMD monitoring efforts in pig 
populations.  Upcoming collaborations are currently planned with 
the Central Veterinary Institute, the Netherlands, and SENASA, 
Argentina, to examine vaccine efficacy of serotype O and A viruses 
in cattle.  
 
GFRA has ensured that FMD research could continue for Australia, 
if not in country, then abroad where resources could be shared.  It is 
AAHL’s vision that these collaborative projects will continue into 
the future and that the FMD field at large will benefit more and more 
from collaborations such as these.  
The Foot-and-Mouth Disease Risk Management Project – AAHL, Australia 
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FMDV ecology in South East Asia  
Collaborative project between DAH-Vietnam and ARS-USDA-Plum Island 
Jonathan Arzt & Luis Rodriguez 
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Department of Agriculture 
 
In 2011, a unique collaboration was established between two GFRA 
partners: the Vietnam Department of Animal Health (DAH) and the 
Agricultural Research Service (ARS) at Plum Island Animal Disease 
Center, USDA. The project entitled “Molecular epidemiology, 
surveillance, and predictive tools for FMD control in Vietnam” is 
aimed at elucidating the ecology of FMDV in Vietnam with 
emphasis on determining the potential role(s) of persistently infected 
cattle and Asian buffalo as carriers of FMDV and sources of new 
outbreaks. These goals were closely aligned with the core vision and 
mission of GFRA, as the activities clearly represented a global 
research partnership with the intention to contribute towards the 
progressive control and eradication of FMD. The establishment of 
this project was facilitated by another GFRA partner: the Australian 
Animal Health Laboratory, who were already working in Vietnam.  
Figure 1: Probang training sessions at slaughterhouses in Ho Chi 
Minh City (left) and near Hanoi (right)  
 
Scant resources were available to tackle this ambitious goal, but with 
the oversight and authority of DAH Headquarters, including 
Principal Investigator Dr. Do Huu Dung, and study design input 
from ARS-USDA, two teams of field investigators were assembled. 
One team would be led by Dr Nguyen Tung and based out of 
National Center for Veterinary Diagnostics (NCVD), Hanoi. The 
other team would be led by Dr. Ngo Thanh Long at Regional Animal 
Health Office No.6 (RAHO6) in Ho Chi Minh City. The teams 
would engage in activities that had overlapping themes, but some 
operational differences. 
 
Both teams set out to conduct targeted surveillance in regions of 
known recent outbreaks. The goal was to identify carriers for various 
downstream research activities. The NCVD team focused on buffalo 
which are present in greater abundance in northern provinces 
whereas the RAHO6 team focused on cattle. Confirmed carriers 
were enrolled in longitudinal analyses, transmission studies, and/or 
necropsy studies.  Although data analysis is still ongoing, initial 
results demonstrated important differences in disease occurrence and 
circulating FMDV strains between locations in northern and 
southern Vietnam.  
Figure 2: Two donor-sentinel pairs from longitudinal transmission 
study  
 
Various forms of data from these activities are intended to be 
available in a handful of manuscripts and meetings in coming 
months and years. But, in short, the collaboration has been a great 
success in various manners. Most importantly, the relationship 
between the two institutions has been established and fortified to 
facilitate ongoing and continuing collaboration. Joint design and 
execution of the sub-projects by DAH and ARS scientists was the 
foundation for the relationship; but, the highly successful output 
delivery cemented the positive experience. The productivity of this 
new relationship is reflected in a newly awarded grant to support 
another four years of follow-up research. Additionally, several new 
technologies were delivered from ARS to DAH which have now 
been expertly incorporated into routine diagnostics and research 
practices. These new practices combined with the dedication of 
DAH and ARS scientists ensure the future success and productivity 
of this partnership.  
 
Figure 3: Carrier 
buffalo in Lang Son 
province  
Mariano Perez-Filgueira 
 
INTA, Institute of Virology, Buenos Aires, Argentina  
 
The FMDV strains A/Argentina/2000 (A/Arg/00) and A/
Argentina/2001 (A/Arg/01) were isolated from infected bovines 
during the 2000–2001 FMDV epidemics that occurred in Argentina. 
While strain A/Arg/00 was said to produce mild lesions in the 
affected animals, strain A/Arg/01 caused severe lesions in cattle in 
the field as well as in experimental challenge trials. In order to 
identify viral genetic determinants of the differential virulence 
displayed by both FMDV isolates, a molecular clone of A/Arg/01 
strain and viral chimeras containing the S-fragment or the internal 
ribosome entry site (IRES) of A/Arg/00 in the A/Arg/01 backbone 
were constructed (A2001clone) and characterised in terms of plaque 
size and replication kinetics in cell culture. The IRES appeared as a 
determining factor of the lower level of A/Arg/00 replication in 
BHK-21 cells. High-throughput RNA probing revealed structural 
differences between both IRESs, which in turn were differentially 
modulated by the viral 3´untranslated region (3´UTR), as determined 
by in vitro and in vivo translation experiments. These data support a 
role of the IRES-3’UTR modulation in determining the level of 
FMDV replication in field strains (García Núñez et al., Virology 
448:303-313, 2014). 
 
More recently, we demonstrated that FMDV strain A/Arg/01 was 
more pathogenic than A2001clone in mice, in spite of the fact that 
these viruses shared similar growth properties in cell culture. 
Sequence comparison studies showed 6 amino acid changes in the 
polyprotein (in viral proteins VP2, VP1 and 2C) and 26 synonymous 
changes throughout the viral genome between the parental FMDV 
strain and A2001clone. Experiments are in progress in order to 
evaluate the role of each amino acid change on the lethality of 
FMDV in adult mice. 
Viral determinants of pathogenesis and virulence of FMDV  
Collaborative project between PIADC-ARS (USA), the CBMSO (Spain) and the Institute of 
Biotechnology-INTA (Argentina) 
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In the past year, the National Centres for Animal Disease (NCAD, 
Winnipeg and Lethbridge) have focused their efforts on developing 
and/or improving specific FMDV diagnostic tests. In a recent study, 
a panel of monoclonal antibodies (mAbs) was produced and used in 
an antigen detection ELISA for the characterisation of new isolates 
of FMDV serotype O. The mAbs were characterised using peptide 
array and mAb resistant mutant selection. Seven out of nine mAbs 
reacting with 5 known antigenic sites and two other non-neutralising 
mAbs were identified. The mAbs were then evaluated by antigen 
detection ELISA for the detection of 46 FMDV serotype O isolates 
representing 7 of 10 known topotypes. This panel of mAbs is useful 
for monitoring the emergence of antigenically distinct strains and 
determination of relevant antigenic site differences.  
 
A panel of FMDV serotype A specific mAbs has also been 
developed. These were examined for their ability to compete with a 
polyclonal anti-serum from cattle experimentally inoculated with 
FMDV serotype A. The aim was to develop a sensitive and specific 
serotype A competitive ELISA. Two mAbs  were selected and are  
currently being evaluated in the competitive ELISA. 
 
Additionally, the mAbs generated at the NCAD have been used in 
the development of rapid lateral flow strip tests for pen‑side 
diagnosis of FMDV and the development of a rapid immunoassay 
method for quantitatively measuring FMDV particles in infected 
cultures. Some mAbs have also been supplied to other laboratories 
for various purposes. 
 
The NCAD is also investigating the feasibility and suitability of a 
poly-specific virus capture Apolipoprotein H-enzyme-linked 
immunosorbent assay (ApoH-ELISA) for detection of FMDV and 
other vesicular disease viruses. FMDV and SVDV particles were 
shown to bind to ApoH-coated plates based on real-time reverse 
transcription polymerase chain reaction amplification of RNA 
extracted from contents of the plate. Preliminary results show that 
using ApoH-ELISA for FMDV detection is comparable to the 
conventional FMDV antigen detection. 
 
A multiplex assay for simultaneous detection of seven swine viruses 
(FMDV, SVDV, VESV, CSFV, ASFV, PCV2, PRRSV) and an 
FMDV typing assay were developed for a user-friendly electronic 
microarray system that integrates and automates capture probe 
printing, amplicon hybridization, washing and reporting. The user 
friendly multiplex assay successfully detected 60 strains of the seven 
targeted viruses, including 23 strains of FMDV representing all 
seven serotypes. No reactivity was observed with a panel of bacteria 
and viruses associated with livestock and oral swab material from 
healthy pigs. The assay was also able to detect the presence of viral 
nucleic acids of all seven viruses in clinical samples from 
experimentally infected animals or biological material inoculated 
with the target viruses. The FMDV typing assay accurately 
identified the serotype of 23 FMDV strains representing all seven 
serotypes. These assays are being adapted to new instrument 
platforms that can fully automate the entire work flow so that no 
user handling is required after sample introduction. 
 
Other projects in the NCAD labs include enhancing the replication 
of FMDV in cell-lines by genetic engineering and development of 
multiplex bead-based assays for simultaneous diagnosis of vesicular 
diseases in swine. 
The NCAD continues to collaborate with other laboratories within 
the GFRA. Specifically, there was collaboration with the 
Investigation and Diagnostic Centre, Ministry for Primary Industries, 
New Zealand on the evaluation of diagnostic tests for FMD in red 
deer. The multiplex assay for simultaneous detection of seven swine 
viruses was developed in collaboration with the Pirbright Institute, 
UK, the EU-Reference Laboratory for CSF, Germany and Plum 
Island Animal Disease Center, USA. There is ongoing collaboration 
with CSIRO, Australian Animal Health Laboratory on the evaluation 
of FMD vaccines in sheep. Reagents and samples generated at the 
NCAD have been shared with other laboratories, including APHIS/
USDA, Laboratório Nacional Agropecuário, Brasil, and industry 
partners. A test method for FMD developed at the NCAD is in the 
process of being licensed. 
 
LAB PROFILES 
National Centres for Animal Disease, Canadian Food Inspection Agency                                                      
Winnipeg-Manitoba and Lethbridge-Alberta, Canada 
CODA-CERVA, Belgium  
David Lefebvre  
 
New projects: 
 
 ‘Rapid Antiviral Containment of Epidemics of Classical Swine 
Fever and Foot-and Mouth Disease’ (EraSME-RACE), started 
September 1st 2013, funded by the Flemish Agency for Innova-
tion by Science and Technology, beneficiary Aratana NV, re-
search partners CODA-CERVA and Synovo GmbH 
 ‘Mechanism of action and barrier to resistance of antiviral 
drugs for foot-and-mouth disease virus and classical and Afri-
can swine fever virus’ (ANTIVIRES), started January 1st 2014, 
funded by the Belgian Federal Public Service for Health, Food 
chain safety and Environment, beneficiary CODA-CERVA, 
research partners Aratana NV and the University of Leuven, 
Belgium 
 
International collaborations: 
 
 An OIE Twinning project between CODA-CERVA and the 
NVRI from Vom, Nigeria, was officially approved in June 2014 
by the OIE. 
 In July-August, CODA-CERVA will provide a 2-week training 
course to a person from BVI, Botswana in the framework of a 
bilateral collaboration on quality control of methods used for 
diagnosis and for vaccine evaluation. 
 
Science reports: 
 
Research articles specific for FMDV: 
 A manuscript from CODA-CERVA entitled ‘A refined Guinea 
pig model of foot-and-mouth disease virus infection for assess-
ing the efficacy of antiviral compounds’ by De Vleeschauwer et 
al. has been accepted in June 2014 for publication in the journal 
‘Transboundary and Emerging Diseases’ (TBED). 
 An article entitled ‘In vitro surrogate models to aid in the devel-
opment of antivirals for the containment of foot-and-mouth 
disease outbreaks’ with CODA-CERVA as co-authors has been 
published very recently in the journal ‘Antiviral Re-
search’ (Osiceanu et al., 2014 May;105:59-63). 
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Our laboratory studies immunological aspects of FMDV, BVDV and 
Neospora caninum infections in cattle. The group is composed of 
two post-docs, a laboratory manager and three PhD students. 
Regarding FMD, our research is now focussed in solving practical 
issues related to the application of FMD vaccines in endemic 
settings. 
  
We are dedicated to three main research lines: 
 New serological assessments  
 Immunogenicity of current FMD vaccines in the presence 
of maternal immunity transferred through colostrum 
 Simultaneous application of FMD and other important 
vaccines in cattle 
 
New serological methods 
 
We recognised that in endemic regions where resources are scarce, 
vaccine efficacy and coverage is not monitored correctly due to the 
impossibility of implementing currently used assays for serological 
testing and making their application sustainable over time. These 
assay are the virus neutralisation test (VNT), and the Liquid and 
Solid Phase Blocking ELISAs (LPBE and SPBE, respectively).  Our 
contribution to this problem will be to provide new high-throughput 
tools that developing countries can easily implement for monitoring 
and evaluating vaccination programs. 
 
These tools are four novel ELISAs, three of them are isotype 
ELISAs to titrate isotypes of specific antibodies (Ab) against 
FMDV: IgM, IgG1 and IgG2. The other assay is meant to measure 
specific Ab avidity. In two recently published studies we applied 
these techniques to the indirect evaluation of cross protection using 
type A strains (Lavoria et al Vaccine 2012 Nov 6; 30 (48): 6845. -50 
doi: 10.1016/j.vaccine.2012.09.011; Brito et al, Vaccine 2014 Jan 
16, 32 (4:433-6 doi: 10.1016/j.vaccine.2013.12.007). We 
demonstrated that the combined use of these techniques provides 
more accurate results than measurements made by VNT, the 
recommended standard technique.  
 
Our current aim is to test how avidity and IgG-subtype ELISAs 
perform as indirect predictors of protection compared to currently 
used VNT, SPBE and LPBE. We are now working in collaboration 
with Dr. Francois Marée at the Onderstepoort Veterinary Institute 
(OVI) to apply these assays in the assessment of the immune 
responses induced by SAT-2 vaccination and challenge. It is 
important to note that we have already started the set-up of the 
assays at the OVI.   Last year, I travelled to the OVI to set up the 
avidity ELISA using purified virus prepared by Dr Marée´s group 
and a different peroxidase substrate. Results obtained by the 
application of this ELISA, describing the avidity of different sera in 
epitope-replaced SAT-2 mutants, have already been published 
(Opperman et al J Virol. 2014 May 14. pi: JVI.00470-14). The 
avidity ELISA was set up in three weeks, meaning that this approach 
can be easily applied in any other country.  
We are open to transfer these protocols and help in the set-up of the 
assays within each particular laboratory. This kind of joint project 
will provide information on the kinetics of total Abs, neutralising 
titres, isotypes and avidity maturation after vaccination, and the 
behavior of the immune responses measured by all serological 
assays after experimental infection of naive and vaccinated cattle. 
This basic information will provide a proof-of-principle on the 
potential of these assays in endemic settings. 
Influence of colostrum in the immune responses of calves to FMD 
vaccine 
 
The inactivated vaccine is currently applied to adult animals or 
young animals without maternal antibodies. It has been shown to be 
effective in these age groups, as inactivated vaccines are well-known 
to be unable to stimulate neonatal immunity in the presence of 
maternal antibodies; only cellular responses are obtained with low or 
no induction of specific antibodies. However, field and experimental 
data show contradictory results, while some reports show some 
inhibition by colostral antibodies, others found that purified FMD-oil 
vaccines are able to overcome the inhibitory effects of maternal 
antibodies inducing protective levels of antibodies in young animals. 
 
We have recently published a study on the immune responses 
induced by vaccination and re-vaccination in calves with maternal 
antibodies (Mat-Abs). Calves with or without colostral antibodies 
were immunised with commercial FMD vaccine. Humoral responses 
were assessed, using traditional and novel techniques. We 
demonstrated that Mat-Abs interfered with the induction of virus 
neutralising responses, while total antibody assessment did not 
reveal the same magnitude of interference (Bucafusco et al.  
Vaccine. 2014 Jun 23. pii: S0264-410X(14)00857-3. doi: 10.1016/
j.vaccine.2014.06.056). We are now presenting a paper at the 
EUFMD open session 2014, where we studied how the presence of 
maternal immune cells influences calves´ immune responses to 
vaccination. 
 
Study the effect of simultaneous application of FMD vaccine 
together with other vaccines in cattle 
 
FMD vaccination in Argentina and other regions within South 
America is performed under the control of the regulatory authorities 
and conducted by certified veterinarians.  These organised 
campaigns may facilitate the controlled application of other vaccines 
against other endemic diseases. There is very little published 
information on the efficacy of FMD vaccines when co-administered 
with other vaccines, particularly live vaccines. We started evaluating 
the simultaneous application of the currently used commercial 
tetravalent oil FMD vaccine used in Argentina together with the 
anthrax live vaccine. We measured total antibodies by LPBE and 
also IgG isotypes. We demonstrated that the combined application of 
these vaccines did not interfere with the antibody FMDV-booster 
responses. Antibody titres were similar in both groups and followed 
comparable kinetics over time. We are now pursuing new studies 
with other vaccines of regional interest. 
 Another proof-of-concept article from CODA-CERVA for 
antiviral drugs in rodents was published online in 2013: Le-
febvre et al., Proof-of-concept for the inhibition of foot-and-
mouth disease virus replication by the antiviral drug                
2’-C-methylcytidine in severe combined immunodeficient 
mice. Transbound Emerg Dis. 2013 Mar 11. doi: 10.1111/
tbed.12069. 
 
Research articles not specific for FMDV: 
 An article entitled ‘Application of a cell-based protease assay 
for testing inhibitors of picornavirus 3C proteases.’ with CODA
-CERVA as co-authors has been published very recently in the 
journal ‘Antiviral Research’ (van der Linden et al., 2014 
Mar;103:17–24). 
 An article from CODA-CERVA entitled 'False positive results 
in metagenomic virus discovery: a strong case for follow-up 
diagnosis’ was recently published online: Rosseel et al., Trans-
bound Emerg Dis. 2014 Jun 10. doi: 10.1111/tbed.12251. 
INTA, Institute of Virology,  Buenos Aires, Argentina  
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Want to know more? 
 
The Global Foot-and-Mouth Disease Research Alliance  
(GFRA)                                                   
  A worldwide association of animal health research    
organisations to assist the global control and  
eventual eradication of foot-and-mouth disease. 
 
www.ars.usda.gov/gfra 
 
 
 
 
 
 
 
 
 
 
The GFRA Executive Committee 
 
Wilna Vosloo   CEO  
   (Australian Animal Health Laboratory – Wilna.vosloo@csiro.au) 
Francois Maree   Outgoing President  
   (Onderstepoort Veterinary Institute, South Africa – mareef@arc.agric.za) 
Long Thanh Ngo  President Elect  
   (Regional Animal Health Laboratory 6, Vietnam – ngothanhlong60@gmail.com)  
Cyril Gay   Executive Secretary  
   (Agricultural Research Service, USA – Cyril.Gay@ARS.USDA.GOV) 
Luis Rodriguez   Science Director  
   (Plum Island Animal Diseases Centre, USA – luis.rodriguez@ars.usda.gov) 
Bryan Charleston  Finance Director  
   (Pirbright Institute, UK – bryan.charleston@pirbright.ac.uk) 
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Australian Animal 
Health  Laboratory           
September 2014              The Pirbright Institute Centenary Conference 
   Guildford United Kingdom,  11–12  September 2014 
 
October 2014  Open Session of the EuFMD 
   Cavtat, Croatia,  29–31 October 2014 
 
November 2014 Reference Lab Network Meeting 
   Brescia, Italy,  26–27 November 2014 
 
2015   GFRA Biennial Meeting 
   Vietnam,  TBA 
